|
시장보고서
상품코드
2075780
골수증식성 종양 치료 시장 : 질환별, 약제 클래스별, 유통 채널별, 지역별Myeloproliferative Neoplasms Treatment Market, By Disease Type, By Drug Class, By Distribution Channel, By Geography |
||||||
골수증식성 종양 치료 시장은 2026년에 101억 1,000만 달러 규모에 이를 것으로 추정되며, 2033년까지 133억 9,000만 달러에 이를 것으로 예상되고 있습니다. 2026-2033년 CAGR 4.1%로 성장할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 시장 규모(2026년) : | 101억 1,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) : | 4.10% | 시장 규모 예측(2033년) : | 133억 9,000만 달러 |
골수증식성 종양은 혈액 세포의 수가 증가하는 원인이 되는 골수에서 발생하는 드문 질환군입니다. 골수증식성 종양에 수반되는 증상으로는 잦은 두통, 피로감, 멍이나 비정상적인 출혈, 시력 저하나 이명 등의 눈 관련 이상, 평소보다 감염에 취약해지는 것 등이 있습니다. 또한, 골수증식성 종양의 진단을 위해 혈액 검사가 실시됩니다. 이 검사를 통해 혈액 세포의 수를 확인할 수 있을 뿐만 아니라, 유전자 변이의 유무도 확인할 수 있습니다. 또한, 골수 검사나 복부 초음파 검사 등 다른 검사도 실시됩니다.
골수증식성 질환의 유형에 따라 골수에서 생성되는 혈액 세포는 다릅니다. 골수란 뼈 내부에 있는 부드러운 부분으로, 혈액 세포를 생성하는 곳입니다. 골수증식성 질환에는 다음과 같은 다양한 유형이 있습니다.
- 만성 골수성 백혈병(CML).
- 진성 적혈구 증가증.
- 본태성 혈소판 증가증.
- 원발성 골수섬유증.
시장 역학
골수증식성 종양 치료 업계의 주요 기업들은 골수증식성 종양에 대한 혁신적인 치료법을 개발하기 위한 연구 개발에 주력하고 있습니다. 따라서, 시장 내 연구개발 활동 증가가 예측 기간 동안 전 세계 골수증식성 종양 치료 시장의 성장을 견인할 것으로 예측됩니다. 예를 들어, 2023년 2월 23일, 대만에 거점을 두고 심도 있는 전문 지식과 검증된 과학적 원리를 활용하여 혈액학 및 종양학 분야의 신규 생물학적 제제를 제공하는 세계적인 바이오의약품 혁신 기업인 PharmaEssentia Corporation의 자회사인 PharmaEssentia USA Corporation은 본태성 혈소판 증가증(ET) 성인 환자를 대상으로 한 로페긴터페론 알파-2b-njft 치료에 대한 2b상 임상시험에서 현재 첫 번째 환자에 대한 투여가 시작되었다고 발표했습니다. BESREMi(로페긴터페론 알파-2b-njft)는 혁신적인 모노페길화된 지속형 인터페론입니다. 독자적인 페길화 기술을 통해 BESREMi는 체내에서 장기간 작용하며, 2주에 1회(또는 최소 1년간 혈액학적 안정성이 유지되는 경우 4주에 1회) 투여를 목표로 하고 있어, 환자 개개인의 필요에 맞춘 유연한 투여가 가능합니다.
본 조사의 주요 특징 :
- 본 보고서에서는 세계의 골수증식성 종양 치료 시장에 대한 상세한 분석을 수행하였으며, 2025년을 기준 연도로 하여 2026-2033년 예측 기간 동안 시장 규모 및 연평균 성장률(CAGR)을 제시하고 있습니다. 또한, 각 부문별 잠재적 수익 기회를 파악하는 한편, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 세계의 골수증식성 종양 치료 시장의 주요 업체들을 분석했습니다.
- 이 보고서에서 얻을 수 있는 인사이트은 기업의 마케팅 담당자 및 경영진이 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 기반한 의사결정을 내릴 수 있도록 돕습니다.
- 세계의 골수증식성 종양 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 골수증식성 종양 치료 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적 및 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 골수증식성 종양 치료 시장 : 질환 유형별(2021-2033년)
제5장 세계의 골수증식성 종양 치료 시장 : 약제 클래스별(2021-2033년)
제6장 세계의 골수증식성 종양 치료 시장 : 유통 채널별(2021-2033년)
제7장 세계의 골수증식성 종양 치료 시장 : 지역별(2021-2033년)
제8장 경쟁 구도
제9장 섹션
AJY 26.07.09Myeloproliferative Neoplasms Treatment Market is estimated to be valued at USD 10.11 Bn in 2026 and is expected to reach USD 13.39 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 10.11 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.10% | 2033 Value Projection: | USD 13.39 Bn |
Myeloproliferative neoplasms are a group of rare disorders of the bone marrow that cause an increase in the number of blood cells. The symptoms associated with Myeloproliferative Neoplasms include frequent headaches, tiredness, bruising or unusual bleeding, problem with eyes - such as blurred vision, ringing in the ears, getting more infectious than usual. Moreover, the diagnosis involves blood test to diagnose myeloproliferative neoplasms, the blood tests show the number of blood cells, and can look for genetic mutations. Also, there are other test which done like a bone marrow test, an ultrasound of abdomen.
Different myeloproliferative disorders affect different blood cells that form in the bone marrow. The bone marrow is the soft inner part of bones that makes the blood cells. There are number of different types of myeloproliferative disorders exist, which are;
- Chronic myeloid leukaemia (CML)
- Polycythaemia vera
- Essential thrombocythaemia
- Primary myelofibrosis
Market Dynamics
The key players in the myeloproliferative neoplasm treatment industry are focusing on research and development to develop innovative treatment for myeloproliferative neoplasm. Thus, an increase in research and developement activities in the market is expected to drive the global myeloproliferative neoplasms treatement market growth over the forecast period. For instance, on February 23, 2023, PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation, a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced that the first patient is now being dosed in a phase 2b clinical study evaluating ropeginterferon alfa-2b-njft for the treatment of adults with essential thrombocythemia (ET). BESREMi (ropeginterferon alfa-2b-njft) is innovative monopegylated, long-acting interferon. With its unique pegylation technology, BESREMi has a long duration of activity in the body and is aimed to be administered once every two weeks (or every four weeks with hematological stability for at least one year), allowing flexible dosing that helps meet the individual needs of patients.
Key features of the study:
- This report provides an in-depth analysis of the global myeloproliferative neoplasms treatment market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period 2026-2033, considering 2025 as the base year. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global myeloproliferative neoplasms treatment market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Novartis AG, PharmaEssentia Corporation, Bristol Myers Squibb, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Incyte, Johnson & Johnson, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche AG, Gamida Cell, Sierra Oncology, Inc, CTI BioPharma Corp, Imago BioSciences, AbbVie Inc, and Constellation Pharmaceuticals
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global myeloproliferative neoplasms treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global myeloproliferative neoplasms treatment
Detailed Segmentation:
- Global Myeloproliferative Neoplasms Treatment Market, By Disease Type (Revenue, USD Bn, 2021 - 2033)
- Essential Thrombocythemia (ET)
- Myelofibrosis (MF)
- Polycythemia Vera (PV)
- Global Myeloproliferative Neoplasms Treatment Market, By Drug Class (Revenue, USD Bn, 2021 - 2033)
- Tyrosine Kinase Inhibitors
- Janus kinase inhibitors (JAKi)
- Antimetabolites
- Others (alkylating agents, etc.)
- Global Myeloproliferative Neoplasms Treatment Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles
- Novartis AG
- Pharma
- Essentia Corporation
- Bristol Myers Squibb
- Pfizer, Inc.
- Takeda Pharmaceutical Company Limited
- Incyte
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd,
- F. Hoffmann-La Roche AG
- Gamida Cell
- Sierra Oncology, Inc
- CTI BioPharma Corp
- Imago BioSciences
- AbbVie Inc
- Constellation Pharmaceuticals
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Disease Type
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Regulatory Scenario
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Myeloproliferative Neoplasms Treatment Market, By Disease Type, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Essential Thrombocythemia (ET)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Myelofibrosis (MF)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Polycythemia Vera (PV)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
5. Global Myeloproliferative Neoplasms Treatment Market, By Drug Class, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Tyrosine Kinase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Janus Kinase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Antimetabolites
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Segment Trends
6. Global Myeloproliferative Neoplasms Treatment Market, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
7. Global Myeloproliferative Neoplasms Treatment Market, By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Region/Country, 2021 -2033, (US$ Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- Novartis AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- PharmaEssentia Corporation
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bristol Myers Squibb
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Incyte
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- F. Hoffmann-La Roche AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Gamida Cell
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sierra Oncology, Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- CTI BioPharma Corp
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Imago BioSciences
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- AbbVie Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Constellation Pharmaceuticals
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novartis AG
9. Section
- References
- Research Methodology
- About us and Sales Contact
